Oncocross Co., Ltd. (KOSDAQ:382150)

South Korea flag South Korea · Delayed Price · Currency is KRW
9,040.00
-110.00 (-1.20%)
Apr 29, 2026, 3:30 PM KST
-28.87%
Market Cap 111.59B
Revenue (ttm) 370.46M
Net Income (ttm) -8.93B
Shares Out 12.20M
EPS (ttm) -747.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 225,827
Average Volume 1,115,521
Open 9,200.00
Previous Close 9,150.00
Day's Range 8,990.00 - 9,210.00
52-Week Range 6,150.00 - 15,470.00
Beta n/a
RSI 62.34
Earnings Date May 14, 2026

About Oncocross

Oncocross Co., Ltd. develops drugs for the treatment of cancers, rare diseases, and intractable diseases in South Korea. Its products pipeline includes OC101 for liver cirrhosis; OC101+OC111 for non-alcoholic steatohepatitis; OC201+OC202e for Inhibition of cancer metastasis; OC211, a Pan-KRAS Inhibitor; OC221, an immuno-oncology combination; OC514 to treat amyotrophic lateral sclerosis and Duchenne muscular dystrophy; and OC701 to treat atopic dermatitis. The company is also developing OJP3101 for metabolic disease; OJP3101 for Cardiovascular D... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 382150
Full Company Profile

Financial Performance

In 2025, Oncocross's revenue was 370.46 million, a decrease of -65.45% compared to the previous year's 1.07 billion. Losses were -8.93 billion, 37.7% more than in 2024.

Financial Statements

News

There is no news available yet.